Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

IMS 2022 | COSMOS: characterizing the biology of smoldering myeloma for early detection of symptomatic myeloma

Karthik Ramasamy • 30 Sep 2022

IMS 2022

Multiple Myeloma Rare Diseases Smoldering Myeloma

COSMOS

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the aims and design of the COSMOS study, which aims to better understand the biology of smoldering myeloma in order to detect patients at a high risk of progression to symptomatic myeloma early and effectively prevent progression. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Novel agents to improve outcomes for patients with multiple myeloma in the salvage setting

Karthik Ramasamy • 20 Dec 2023

Optimizing maintenance therapy in multiple myeloma: an analysis from the PREAMBLE registry

Karthik Ramasamy • 20 Dec 2023

RADAR: guiding treatment for NDMM with MRD and genetic risk

Karthik Ramasamy • 20 Dec 2023

OxCOM: monitoring monoclonal gammopathies for progression to active myeloma

Karthik Ramasamy • 20 Dec 2023

Related Videos

MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting

Ola Landgren • 13 Apr 2024

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

Personalized risk assessment for transplantation in primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024